Core Viewpoint - The company plans to sign a technology cooperation development contract with Nanjing University to jointly develop an anti-thrombotic small nucleic acid drug, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay a percentage of the annual revenue from the drug to Nanjing University for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, suggesting an imminent surge in the domestic market [1] - The company's strategic focus on cardiovascular treatments aligns well with the development of the new drug, enhancing its core competitiveness in research and injecting new momentum into its innovative drug portfolio [1]

Core Viewpoint - The company plans to sign a technology cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Group 1: Company Strategy - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan [1] - Upon successful development and market launch of the target drug, the company will pay a percentage of the annual revenue from the drug to Nanjing University for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Group 2: Market Opportunity - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of domestic small nucleic acid drugs is progressing rapidly, and the market is expected to experience rapid growth [1] - The company aims to seize market opportunities by understanding local market demands and developing products tailored to domestic patients, aligning with its strategic planning in the cardiovascular treatment field [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, announced a collaboration with Nanjing University to develop "anti-thrombotic small nucleic acid drugs" with an investment of 15 million yuan [1] Group 1: Collaboration Details - The project is currently in the preliminary research stage and involves signing a technical cooperation development contract with Nanjing University [1] - The collaboration aims to conduct various preclinical research phases, including pharmacodynamic validation and drug-like property assessment of the target sequence [1] Group 2: Research Complexity - The research and development process is complex and involves multiple uncertainties, indicating potential challenges ahead [1]

Core Viewpoint - The company plans to sign a technical cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, and the domestic market is expected to experience rapid growth [1] - The company's early entry into the small nucleic acid drug field is aimed at seizing market opportunities, supported by a deep understanding of local market demands and the strategic alignment with its cardiovascular treatment focus [1]

Core Viewpoint - The company plans to collaborate with Nanjing University for the joint development of "anti-thrombotic small nucleic acid drugs," with a transaction amount of 15 million yuan [1] Group 1 - The collaboration aims to leverage academic research for drug development [1] - The transaction amount indicates a significant investment in innovative pharmaceutical research [1]

Core Viewpoint - Company plans to sign a technology cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, positioning the company to seize market opportunities [1] - The target drug aligns with the company's strategic planning in the cardiovascular treatment field, enhancing its core competitiveness in research and injecting new momentum into the innovation drug product pipeline [1]